Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Financings Routine −

Avicanna Announces Closing of Non-Brokered Private Placement

Avicanna closes $600K dilutive placement at a premium to market, but cash runway remains precarious amid persistent burn.

By The Northwire Desk — AI Analysis Jun 12, 2026 · 17:30 AVCN · 0.125 AVICANNA INC. J
Executive Summary
  • Closing of a non-brokered private placement offering 4,000,014 units at $0.15 per unit.
  • Gross proceeds of approximately $600,002.
  • Each unit consists of one common share and a half warrant.
  • Warrants are exercisable at $0.20 per share until June 12, 2029.
  • Proceeds allocated to general working capital, G&A, production/manufacturing, and R&D/clinical development.
  • Subject to a four-month hold period and TSX approval.
Material Impact
  • The financing provides ~$600k in additional runway, extending operations by a few months given the ~$1M/quarter burn rate. It is a routine capital raise for a cash-burning micro-cap. The stock's -21% decline into the print shows the market was already pricing in dilution. The $0.15 placement price is a modest premium to the $0.11 market, but the issuance of warrants and ongoing cash needs limit upside. Not material.
AVCN · Price
Company Overview
  • Avicanna Inc. is a Canadian medical cannabis and biopharmaceutical company. Focus on proprietary cannabinoid formulations, MyMedi.ca platform, and clinical pipeline. Operations in Canada, Colombia, and international exports.
Read the original news release →

More from AVICANNA INC. J

Jun 15, 2026 · 08:30

Splash's $300K strategic bet validates Avicanna's pivot, but liquidity and dilution overhangs keep the stock in a holding pattern.

M&A / Property May 14, 2026 · 07:30

Avicanna Revenue Growth Masks Profitability Regression as Liquidity Improves

Earnings Apr 28, 2026 · 07:28

U.S. Rescheduling Confirmed, but Liquidity Overhang Caps Immediate Upside

Regulatory Apr 20, 2026 · 09:00

Avicanna Earnings Mask Revenue Stagnation as Stock Tests Support Levels

Other Apr 01, 2026 · 18:09

Avicanna omits 2025 net P&L in NR, talks revenue

Earnings Apr 01, 2026 · 07:30

Avicanna Reports Full Year 2025 Audited Financial Statements

Earnings